Genetic disruption of p38α Tyr323 phosphorylation prevents T-cell receptor-mediated p38α activation and impairs interferon-γ production

Blood

Volumn 113, Issue 10, 2009, Pages 2229-2237

  Jirmanova, Ludmila ^a   Sarma, Dandapantula N ^a   Jankovic, Dragana ^b   Mittelstadt, Paul R ^a   D Ashwell, Jonathan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE 14; PHENYLALANINE; T LYMPHOCYTE RECEPTOR; TYROSINE; ISOENZYME; LYMPHOCYTE ANTIGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CELL CYCLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; ENZYME ACTIVATION; GENE ACTIVATION; GENE DISRUPTION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; WILD TYPE; ANIMAL; BIOSYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FLOW CYTOMETRY; GENE TARGETING; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL CYCLE; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE KNOCK-IN TECHNIQUES; INTERFERON-GAMMA; ISOENZYMES; LYMPHOCYTE ACTIVATION; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; TH1 CELLS;

EID: 64049117360     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-153304     Document Type: Article

References (50)

1. Jiang Y, Chen C, Li Z, et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem. 1996;271:17920-17926.
2. Li Z, Jiang Y, Ulevitch RJ, Han J. The primary structure of p38 gamma: a new member of p38 group of MAP kinases. Biochem Biophys Res Commun. 1996;228:334-340.
3. Wang XS, Diener K, Manthey CL, et al. Molecular cloning and characterization of a novel p38 mito-gen-activated protein kinase. J Biol Chem. 1997; 272:23668-23674.
4. Ashwell JD. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol. 2006;6:532-540.
5. Ward SG, Parry RV, Matthews J, O'Neill L. Ap38 MAP kinase inhibitor SB203580 inhibits CD28-dependent T cell proliferation and IL-2 production. Biochem Soc Trans. 1997;25:304S.
6. Zhang J, Salojin KV, Gao JX, Cameron MJ, Bergerot I, Delovitch TL. p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation in primary murine T cells. J Immunol. 1999;162:3819-3829.
7. Salvador JM, Mittelstadt PR, Belova GI, Fornace AJJ, Ashwell JD. The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway. Nat Immunol. 2005;6:396-402.
8. Salvador JM, Hollander MC, Nguyen AT, et al. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity. 2002;16: 499-508.
9. Rincón M, Enslen H, Raingeaud J, et al. Inter-feron- gammaexpression byTh1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J. 1998;17:2817-2829.
10. Kim JM, White JM, ShawAS, Sleckman BP. MAPK p38 alpha is dispensable for lymphocyte development and proliferation. J Immunol. 2005; 174:1239-1244.
11. Berenson LS, Yang J, Sleckman BP, Murphy TL, Murphy KM. Selective requirement of p38alpha MAPK in cytokine-dependent, but not antigen re-ceptor-dependent, Th1 responses. J Immunol. 2006;176:4616-4621.
12. Rincon M. MAP-kinase signaling pathways in T cells. Curr Opin Immunol. 2001;13:339-345.
13. Harper SJ, LoGrasso P. Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell Signal. 2001; 13:299-310.
14. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem. 1998;273:1741-1748.
15. Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell. 1997; 90:859-869.
16. Shibuya H, Yamaguchi K, Shirakabe K, et al. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science. 1996;272: 1179-1182.
17. Salvador JM, Mittelstadt PR, Guszczynski T, et al. Alternative p38 activation pathway mediated byT cell receptor-proximal tyrosine kinases. Nat Immunol. 2005;6:390-395.
18. Grunvald E, ChiaramonteM, HienyS, et al. Biochemical characterization and protein kinase C dependency of monokine-inducing activities of Toxoplasmagondii. Infect Immun. 1996;64:2010-2018.
19. Allen M, Svensson L, Roach M, Hambor J, McNeish J, Gabel CA. Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med. 2000;191:859-870.
20. Diehl NL, Enslen H, Fortner KA, et al. Activation of the p38 mitogen-activated protein kinase pathway arrests cell cycle progression and differentiation of immature thymocytes in vivo. J Exp Med. 2000;191:321-334.
21. Mulroy T, Sen J. p38 MAP kinase activity modulates alpha beta Tcell development. Eur J Immunol. 2001;31:3056-3063.
22. Thompson HL, Marshall CJ, Saklatvala J. Characterization of two different forms of mitogen-activated protein kinase kinase induced in poly-morphonuclear leukocytes after stimulation by N-formylmethionyl-leucyl-phenylalanine or granu-locyte-macrophage colony-stimulating factor. J Biol Chem. 1994;269:9486-9492.
23. 2+-induced p38/SAPK signalling inhibited by the immunosuppressant cyclosporin A in human peripheral blood mononuclear cells. Eur J Bio-chem. 1999;265:1075-1084.
24. Taher MM, Oakley JD, Hershey C, Valerie K. Activation of NF-kappa B and p38 MAP kinase is not sufficient for triggering efficient HIV gene expression in response to stress. Biochemistry. 2000;39: 1709-1715.
25. Hehner SP, Hofmann TG, Dienz O, Droge W, Schmitz ML. Tyrosine- phosphorylated Vav1 as a point of integration for T-cell receptor-and CD28-mediated activation of JNK, p38, and interleu-kin-2 transcription. J Biol Chem. 2000;275:18160-18171.
26. Franklin RA,TordaiA, Patel H, Gardner AM, Johnson GL, Gelfand EW. Ligation of the T cell receptor complex results in activation of the Ras/ Raf-1/MEK/MAPK cascade in human Tlympho-cytes. J Clin Invest. 1994;93:2134-2140.
27. Kwon TK, Buchholz MA, Ponsalle P, Chrest FJ, Nordin AA. The regulation of p27Kip1 expression following the polyclonal activation of murine G0 T cells. J Immunol. 1997;158:5642-5648.
28. Cheng N, Janumyan YM, Didion L, Van Hofwegen C, Yang E, Knudson CM. Bcl-2 inhibition of T-cell proliferation is related to prolonged T-cell survival. Oncogene. 2004;23:3770-3780.
29. Yu JJ, Tripp CS, Russell JH. Regulation and phe-notype of an innate Th1 cell: role of cytokines and the p38 kinase pathway. J Immunol. 2003;171: 6112-6118.
30. KoprakS, Staruch MJ, Dumont FJ. A specific in hibitor of the p38 mitogen activated protein ki-nase affects differentially the production of various cytokines by activated human T cells: dependence on CD28 signaling and preferential inhibition of IL-10 production. Cell Immunol. 1999; 192:87-95.
31. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science. 2002;295:338-342.
32. Grogan JL, Locksley RM. Thelper cell differentiation: on again, off again. Curr Opin Immunol. 2002;14:366-372.
33. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by ki-nase-mediated interaction of T-bet with GATA-3. Science. 2005;307:430-433.
34. Sher A, Collazzo C, Scanga C, Jankovic D, Yap G, Aliberti J. Induction and regulation of IL-12-dependent host resistance to Toxoplasma gondii. Immunol Res. 2003;27:521-528.
35. Wang Z, Harkins PC, Ulevitch RJ, Han J, Cobb MH, Goldsmith EJ. The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. Proc Natl Acad Sci USA. 1997;94:2327-2332.
36. Ge B, Gram H, Di Padova F, et al. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science. 2002;295:1291-1294.
37. Diskin R, Askari N, Capone R, Engelberg D, Livnah O. Active mutants of the human p38alpha mitogen-activated protein kinase. J Biol Chem. 2004;279:47040-47049.
38. Diskin R, Lebendiker M, Engelberg D, Livnah O. Structures of p38alpha active mutants reveal con-formational changes in L16 loop that induce auto-phosphorylation and activation. J Mol Biol. 2007; 365:66-76.
39. Jirmanova L, Jankovic D, Fornace AJJ, Ashwell JD. Gadd45alpha regulates p38-dependent den-dritic cell cytokine production and Th1 differentiation. J Immunol. 2007;178:4153-4158.
40. Sheikh MS, Hollander MC, Fornace AJJ. Role of Gadd45 in apoptosis. Biochem Pharmacol. 2000; 59:43-45.
41. Hildesheim J, Bulavin DV, Anver MR, et al. Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res. 2002; 62:7305-7315.
42. Round JL, Humphries LA, Tomassian T, Mittelstadt P, Zhang M, Miceli MC. Scaffold protein Dlgh1 coordinates alternative p38 kinase activation, directing T cell receptor signals toward NFAT but not NF-kappaB transcription factors. Nat Immunol. 2007;8:154-161.
43. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003;424:223-228
44. Lea NC, Orr SJ, Stoeber K, et al. Commitment point during G0->G1 that controls entry into the cell cycle. Mol Cell Biol. 2003;23:2351-2361.
45. Modiano JF, Mayor J, Ball C, Fuentes MK, Linthicum DS. CDK4 expression and activity are required for cytokine responsiveness in T cells. J Immunol. 2000;165:6693-6702.
46. Trdik D, Djaborkhel R, NagyA, EckschlagerT, Raska I, Muller J. Cyclin D-cdk6 complex is targeted by p21(WAF) in growth-arrested lymphoma cells. J Struct Biol. 2002;140:49-56.
47. Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phos-phorylation. J Biol Chem. 2002;277:29792-29802.
48. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem. 2003;278: 25752-25757.
49. Järviluoma A, Child ES, Sarek G, et al. Phosphor-ylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest. Mol Cell Biol. 2006;26:2430-2440.
50. Hale KK, Trollinger D, Rihanek M, Manthey CL. Differential expression and activation of p38 mito-gen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J Immunol. 1999;162:4246-4252.